Arden sarah (7 resultados)

PAP. Condición: New. New Book. Shipped from UK. Established seller since 2000.

Hardcover. Condición: Good. Estado de la sobrecubierta: Fair. Revised edition. 368pp. Blue cloth-covered boards with gilt lettering and decorations front and spine. 8vo. Cloth is a little worn and unevenly faded, gently rubbed on extreme corners and rounded at spine ends. Some spotting on text block edges and first and last few pages else internally neat, clean, bright and tight. In its original worn and chapped but largely complete dust wrapper, rubbed and scuffed on corners and ends of sunned spine. A large collection of stories aimed at the younger reader from a selection of children's authors, including several contributions by Noel Streatfeild herself.…

Taschenbuch. Condición: Neu. Neuware - Your first FDA meeting could shape the future of your entire development program.But many biotech teams prepare for it as a regulatory event rather than a strategic decision point.They focus on the meeting request, briefing package, questions, and presentation-without first agreeing on what the company needs to learn, which decisions FDA's feedback must inform, or how the program will respond if the agency takes a different view.The Biotech CEO's Guide to Your First FDA Meeting offers a practical, executive-level framework for preparing more strategically.Written by Nilou Sarah Arden, PhD-a former FDA regulator and global biopharma regulatory leader-the guide helps biotech founders, CEOs, executives, and development teams look beyond the mechanics of the meeting and ask a more important question: What must this FDA interaction enable us to decide Inside, you will learn how to: - Define the decisions for which your company needs FDA input- Identify the most consequential uncertainties in your development plan- Prioritize questions that could materially change the program- Distinguish evidence, assumptions, beliefs, and unresolved uncertainty- Integrate CMC, nonclinical, clinical, and regulatory strategies- Recognize which questions should not be asked-or should not be asked yet- Build a briefing package that supports clear, decision-useful feedback- Prepare for disagreement, conditional advice, and unexpected responses- Decide which commitments should be made now and which can wait- Align the leadership team before entering the meetingThe guide also includes: - A one-page FDA meeting strategy- A five-minute strategic-readiness diagnostic- A CEO checklist for final preparation- A post-meeting framework for turning regulatory feedback into decisions, actions, and organizational learningThis is not a technical manual for writing an FDA briefing package. It is a field guide for leading the decisions around one.Whether your company is preparing for a pre-IND meeting, an initial regulatory interaction, or another consequential FDA milestone, this guide will help you connect regulatory strategy to the wider development pathway-including evidence, manufacturing, clinical planning, capital, sequencing, risk, and future options.Because a successful FDA meeting is not simply one that goes smoothly.It is one that helps the company make better decisions.Part of the Cambase Executive Field Guides series: practical intelligence for the decisions shaping the path from science to patients.…

Condición: New. Print on Demand.

Paperback. Condición: new. Paperback. Your first FDA meeting could shape the future of your entire development program.But many biotech teams prepare for it as a regulatory event rather than a strategic decision point.They focus on the meeting request, briefing package, questions, and presentation-without first agreeing on what the company needs to learn, which decisions FDA's feedback must inform, or how the program will respond if the agency takes a different view.The Biotech CEO's Guide to Your First FDA Meeting offers a practical, executive-level framework for preparing more strategically.Written by Nilou Sarah Arden, PhD-a former FDA regulator and global biopharma regulatory leader-the guide helps biotech founders, CEOs, executives, and development teams look beyond the mechanics of the meeting and ask a more important question: What must this FDA interaction enable us to decide?Inside, you will learn how to: - Define the decisions for which your company needs FDA input- Identify the most consequential uncertainties in your development plan- Prioritize questions that could materially change the program- Distinguish evidence, assumptions, beliefs, and unresolved uncertainty- Integrate CMC, nonclinical, clinical, and regulatory strategies- Recognize which questions should not be asked-or should not be asked yet- Build a briefing package that supports clear, decision-useful feedback- Prepare for disagreement, conditional advice, and unexpected responses- Decide which commitments should be made now and which can wait- Align the leadership team before entering the meetingThe guide also includes: - A one-page FDA meeting strategy- A five-minute strategic-readiness diagnostic- A CEO checklist for final preparation- A post-meeting framework for turning regulatory feedback into decisions, actions, and organizational learningThis is not a technical manual for writing an FDA briefing package. It is a field guide for leading the decisions around one.Whether your company is preparing for a pre-IND meeting, an initial regulatory interaction, or another consequential FDA milestone, this guide will help you connect regulatory strategy to the wider development pathway-including evidence, manufacturing, clinical planning, capital, sequencing, risk, and future options.Because a successful FDA meeting is not simply one that goes smoothly.It is one that helps the company make better decisions.Part of the Cambase Executive Field Guides series: practical intelligence for the decisions shaping the path from science to patients. This item is printed on demand. Shipping may be from multiple locations in the US or from the UK, depending on stock availability.…

Condición: Good. Fine Condition, Illustrated Wraps Sunned.

Paperback. Condición: new. Paperback. Your first FDA meeting could shape the future of your entire development program.But many biotech teams prepare for it as a regulatory event rather than a strategic decision point.They focus on the meeting request, briefing package, questions, and presentation-without first agreeing on what the company needs to learn, which decisions FDA's feedback must inform, or how the program will respond if the agency takes a different view.The Biotech CEO's Guide to Your First FDA Meeting offers a practical, executive-level framework for preparing more strategically.Written by Nilou Sarah Arden, PhD-a former FDA regulator and global biopharma regulatory leader-the guide helps biotech founders, CEOs, executives, and development teams look beyond the mechanics of the meeting and ask a more important question: What must this FDA interaction enable us to decide?Inside, you will learn how to: - Define the decisions for which your company needs FDA input- Identify the most consequential uncertainties in your development plan- Prioritize questions that could materially change the program- Distinguish evidence, assumptions, beliefs, and unresolved uncertainty- Integrate CMC, nonclinical, clinical, and regulatory strategies- Recognize which questions should not be asked-or should not be asked yet- Build a briefing package that supports clear, decision-useful feedback- Prepare for disagreement, conditional advice, and unexpected responses- Decide which commitments should be made now and which can wait- Align the leadership team before entering the meetingThe guide also includes: - A one-page FDA meeting strategy- A five-minute strategic-readiness diagnostic- A CEO checklist for final preparation- A post-meeting framework for turning regulatory feedback into decisions, actions, and organizational learningThis is not a technical manual for writing an FDA briefing package. It is a field guide for leading the decisions around one.Whether your company is preparing for a pre-IND meeting, an initial regulatory interaction, or another consequential FDA milestone, this guide will help you connect regulatory strategy to the wider development pathway-including evidence, manufacturing, clinical planning, capital, sequencing, risk, and future options.Because a successful FDA meeting is not simply one that goes smoothly.It is one that helps the company make better decisions.Part of the Cambase Executive Field Guides series: practical intelligence for the decisions shaping the path from science to patients. This item is printed on demand. Shipping may be from our UK warehouse or from our Australian or US warehouses, depending on stock availability.…